Study (year) | Intervention measures | Dosage | Outcomes | Basic treatment plan | Course of treatment |
---|---|---|---|---|---|
Keith C2019 | Empagliflozin/placebo | 10–25 mg | HcA1c, 24H-SBP/DBP, office SBP/DBP | Basic antihypertensive and hypoglycemic program | 12/24 week |
Kazuomi 2019 | Empagliflozin/placebo | 10Â mg | 24H SBP/DBP, HbA1, body weight | Basic hypoglycemic and antihypertensive drugs, including ARB | 12Â week |
Michael 2015 | Dapagliflozin/placebo | 10Â mg | 24HSBP, office SBP, HbA1c, body weight | Basic hypoglycemic and antihypertensive drugs, including ARB/ACEI | 12Â week |
Tikkanen 2015 | Empagliflozin/placebo | 10/25Â mg | 24H SBP/DBP, office SBP/DBP, 55.1/54.8HbA1, body weight | Basic antihypertensive and hypoglycemic program | 12Â week |
Heerspink 2016 | Dapagliflozin/placebo | 10Â mg | Office SBP/DBP, HbA1, body weight | Basic hypoglycemic and antihypertensive drugs, including ARB/ACEI | 12Â week |
Ferreira 2020 | Empagliflozin/placebo | 10/25Â mg | Office SBP, HbA1, body weight | Basic hypoglycemic and antihypertensive drugs, including diuretics | 14Â week |
LanCheng 2021 | Empagliflozin/placebo | 25Â mg | 24HSBP/DBP, office SBP/DBP | Basic hypoglycemic and antihypertensive drugs | 12Â week |
Amin 2011 | Empagliflozin/placebo | 25Â mg | 24HSBP/DBP | Stop the basic hypoglycemic and antihypertensive regimen 3Â weeks before randomization | 4Â week |
Raymond 2015 | Canagliflozin/placebo | 100/300Â mg | 24HSBP/DBP | Basic hypoglycemic and antihypertensive drugs, including ARB/ACEI | 6Â week |
Weber 2015 | Dapagliflozin/placebo | 10Â mg | Office SBP/DBP, HbA1c, 24H SBP | Basic hypoglycemic and antihypertensive drugs, including ARB/ACEI | 12Â week |